Paratek Pharmaceuticals, based in King Of Prussia, PA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). Their FDA-approved tetracycline class antibiotic, Nuzyra, is designed to treat adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.
With a disciplined team of innovative professionals, Paratek is committed to developing and commercializing new treatment options for complex medical issues, including combating the ongoing pandemic of AMR. Led by CEO Evan Loh, M.D., the company strives to provide life-saving solutions to defeat superbugs and improve public health and national security.
Generated from the website